相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Targeting Fc Receptor-Mediated Effects and the Don't Eat Me Signal with an Oncolytic Virus Expressing an Anti-CD47 Antibody to Treat Metastatic Ovarian Cancer
Lei Tian et al.
CLINICAL CANCER RESEARCH (2022)
Adjuvant oncolytic virotherapy for personalized anti-cancer vaccination
D. G. Roy et al.
NATURE COMMUNICATIONS (2021)
Therapeutic cancer vaccines
Mansi Saxena et al.
NATURE REVIEWS CANCER (2021)
Targeting the myeloid checkpoint receptor SIRPα potentiates innate and adaptive immune responses to promote anti-tumor activity
Tracy C. Kuo et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)
First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers
Branimir Sikic et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy
Amira A. Barkal et al.
NATURE (2019)
Programmable bacteria induce durable tumor regression and systemic antitumor immunity
Sreyan Chowdhury et al.
NATURE MEDICINE (2019)
Oncolytic Viruses Engineered to Enforce Leptin Expression Reprogram Tumor-Infiltrating T Cell Metabolism and Promote Tumor Clearance
Dayana B. Rivadeneira et al.
IMMUNITY (2019)
1232PFunctional systemic CD4 immunity is required for clinical responses to PD-L1/PD-1 blockade therapy
M Zuazo et al.
ANNALS OF ONCOLOGY (2019)
Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer
Yu Pan et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)
Repurposing rotavirus vaccines for intratumoral immunotherapy can overcome resistance to immune checkpoint blockade
Tala Shekarian et al.
SCIENCE TRANSLATIONAL MEDICINE (2019)
Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma
Jason Chesney et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Intravenous delivery of oncolytic reovirus to brain tumor patients immunologically primes for subsequent checkpoint blockade
Adel Samson et al.
SCIENCE TRANSLATIONAL MEDICINE (2018)
CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin's Lymphoma
Ranjana Advani et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Adenovirotherapy Delivering Cytokine and Checkpoint Inhibitor Augments CAR T Cells against Metastatic Head and Neck Cancer
Amanda Rosewell Shaw et al.
MOLECULAR THERAPY (2017)
Localized CD47 blockade enhances immunotherapy for murine melanoma
Jessica R. Ingram et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2017)
Rational combination of oncolytic vaccinia virus and PD-L1 blockade works synergistically to enhance therapeutic efficacy
Zuqiang Liu et al.
NATURE COMMUNICATIONS (2017)
Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy
Antoni Ribas et al.
CELL (2017)
Macrophage Polarization Contributes to Glioblastoma Eradication by Combination Immunovirotherapy and Immune Checkpoint Blockade
Dipongkor Saha et al.
CANCER CELL (2017)
Durable antitumor responses to CD47 blockade require adaptive immune stimulation
Jonathan T. Sockolosky et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)
Immunovirotherapy with vesicular stomatitis virus and PD-L1 blockade enhances therapeutic outcome in murine acute myeloid leukemia
W. Shen et al.
BLOOD (2015)
Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma
Robert H. I. Andtbacka et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Viral Infection of Tumors Overcomes Resistance to PD-1-immunotherapy by Broadening Neoantigenome-directed T-cell Responses
Norman Woller et al.
MOLECULAR THERAPY (2015)
CD47 blockade triggers T cell-mediated destruction of immunogenic tumors
Xiaojuan Liu et al.
NATURE MEDICINE (2015)
Oncolytic viruses: a new class of immunotherapy drugs
Howard L. Kaufman et al.
NATURE REVIEWS DRUG DISCOVERY (2015)
CD47 Agonist Peptides Induce Programmed Cell Death in Refractory Chronic Lymphocytic Leukemia B Cells via PLCγ1 Activation: Evidence from Mice and Humans
Ana-Carolina Martinez-Torres et al.
PLOS MEDICINE (2015)
Anti-CD47 antibody-mediated phagocytosis of cancer by macrophages primes an effective antitumor T-cell response
Diane Tseng et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Engineered SIRPα Variants as Immunotherapeutic Adjuvants to Anticancer Antibodies
Kipp Weiskopf et al.
SCIENCE (2013)
Coxsackievirus B3 Is an Oncolytic Virus with Immunostimulatory Properties That Is Active against Lung Adenocarcinoma
Shohei Miyamoto et al.
CANCER RESEARCH (2012)
Targeted cancer immunotherapy with oncolytic adenovirus coding for a fully human monoclonal antibody specific for CTLA-4
J. D. Dias et al.
GENE THERAPY (2012)
The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors
Stephen B. Willingham et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Therapeutic Antibody Targeting of CD47 Eliminates Human Acute Lymphoblastic Leukemia
Mark P. Chao et al.
CANCER RESEARCH (2011)
CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans
Gregory L. Beatty et al.
SCIENCE (2011)
Anti-CD47 Antibody Synergizes with Rituximab to Promote Phagocytosis and Eradicate Non-Hodgkin Lymphoma
Mark P. Chao et al.
CELL (2010)
CD47 Is an Adverse Prognostic Factor and Therapeutic Antibody Target on Human Acute Myeloid Leukemia Stem Cells
Ravindra Majeti et al.
CELL (2009)
Inhibition of self engulfment through deactivation of myosin-II at the phagocytic synapse between human cells
Richard K. Tsai et al.
JOURNAL OF CELL BIOLOGY (2008)
分享论文
